Syntara Ltd
ASX:SNT

Watchlist Manager
Syntara Ltd Logo
Syntara Ltd
ASX:SNT
Watchlist
Price: 0.03 AUD -3.23% Market Closed
Market Cap: 49m AUD

EV/EBITDA
Enterprise Value to EBITDA

-2.7
Current
-2.1
Median
13
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.7
=
Enterprise Value
33.7m AUD
/
EBITDA
-12.4m AUD
All Countries
Close
Market Cap EV/EBITDA
AU
Syntara Ltd
ASX:SNT
48.7m AUD -2.7
US
Eli Lilly and Co
NYSE:LLY
996.4B USD 36.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
503.4B USD 16.4
CH
Roche Holding AG
SIX:ROG
252.6B CHF 11.5
UK
AstraZeneca PLC
LSE:AZN
211.6B GBP 108.7
CH
Novartis AG
SIX:NOVN
207.5B CHF 11.5
US
Merck & Co Inc
NYSE:MRK
244.9B USD 9.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.3
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
143.2B USD 7.4
EBITDA Growth EV/EBITDA to Growth
AU
Syntara Ltd
ASX:SNT
Average EV/EBITDA: 438.8
Negative Multiple: -2.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.3
2-Years Forward
EV/EBITDA
-1
3-Years Forward
EV/EBITDA
-0.9